Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

It's a good question. I think at this point, Olivia, it's premature to discuss what our strategy would be. I think we would have to assess the landscape out there, what is the interest in the voucher, ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

A fourth tab, called “DEXA cohort 9 four,” contains patient-level data for the top MariTide dose. Cantor analyst Olivia ...

Cantor Fitzgerald analyst Olivia Brayer found supplementary bone marrow density data for Amgen’s obesity candidate MariTide ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

During the last three months, 24 analysts shared their evaluations of Alnylam Pharmaceuticals ALNY, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...